Turke et al.’s (61) study found that a small number of cells (<1%) with MET gene amplification could be detected in samples from NSCLC patients before using EGFR TKIs, while a large number of cells with MET amplification were present after EGFR TKI resistance, indicating that the small fraction of cells with MET gene amplification before treatment ultimately led to resistance. This evidence concerns the gene MET and non-small cell lung carcinoma.